Texas Takes a Historic Step Toward Legal Ibogaine Research

In a landmark move for the future of psychedelic-assisted therapy in the U.S., the Texas House of Representatives has given strong bipartisan support to SB2308/HB3717 — a bill that would fund ibogaine research through a newly established state grant program.

With 141 votes in favor, this is the most significant psychedelic therapy vote in Texas history.

If enacted, this legislation will allocate $50 million to fund FDA-approved clinical trials studying ibogaine’s potential to treat opioid use disorder (OUD), PTSD, traumatic brain injury (TBI), and other serious mental health conditions. The goal: accelerate FDA approval and expand safe, evidence-based access to those in need.

At Beond, we are deeply encouraged by this momentum. As Tom Feegel, CEO and Co-Founder of Beond, shared earlier this year, “This couldn’t be more historic or more important at this moment.”

The legislation reflects growing recognition that traditional treatments often fall short — and that alternative, science-backed therapies like ibogaine deserve rigorous research and public support.

“Ibogaine isn’t just another drug. It’s a whisper of redemption in a single dose… It can mend the broken pieces of a mind ravaged by trauma.”
— Rep. Cody Harris (R), bill sponsor

Texas is again leading the national conversation, building on earlier psychedelic research initiatives like HB1802 and showing what’s possible when science, safety, and service align.

We’re encouraged by this momentum and hopeful that with continued leadership, safety, science, and honoring its cultural roots, this medicine can reach more of those who truly need it.